Letaplimab represents a unique medical approach for managing complement-mediated diseases. This antibody targets complement component C1q, a critical factor of the complement system, potentially inhibit its initial https://cyrusjlqe550641.mpeblog.com/74419134/letaplimab-a-new-clinical-strategy